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Abstract CD4
+ T lymphocytes of patients with chronic
kidney disease (CKD) are characterized by reduced levels
of crucial surface antigens and changes in the cell cycle
parameters. Recombinant human erythropoietin (rhEPO)
normalizes their altered phenotype and proliferative capac-
ity. Mechanisms leading to the deficient responses of T
lymphocytes are still not clear but it is postulated that
immunological changes are deepened by hemodialysis
(HD). Study of activation parameters of CD4
+ T lympho-
cytes in hemodialyzed and predialysis CKD patients could
bring insight into this problem. Two groups of patients,
treated conservatively (predialysis, PD) and hemodialyzed
(HD), as well as healthy controls, were included into the
study; neither had received rhEPO. Proportions of main
CD4
+CD28
+,C D 4
+CD25
+,C D 4
+CD69
+,C D 4
+CD95
+,
and CD4
+HLA-DR
+ lymphocyte subpopulations and pro-
liferation kinetic parameters were measured with flow
cytometry, both ex vivo and in vitro. No differences were
seen in the proportions of main CD4
+ lymphocyte
subpopulations (CD4
+CD28
+,C D 4
+CD25
+,C D 4
+HLA-
DR
+, CD4
+CD69
+, CD4
+CD95
+) between all examined
groups ex vivo. CD4
+ T lymphocytes of HD patients
exhibited significantly decreased expression of co-
stimulatory molecule CD28 and activation markers CD25
and CD69 after stimulation in vitro when compared with
PD patients and healthy controls. HD patients showed also
decreased percentage of CD4
+CD28
+ lymphocytes prolif-
erating in vitro; these cells presented decreased numbers of
finished divisions after 72 h of stimulation in vitro and had
longer G0→G1 time when compared to healthy controls.
CD4
+ T lymphocytes of PD patients and healthy controls
were characterized by similar cell cycle parameters. Our
study shows that repeated hemodialysis procedure influen-
ces phenotype and proliferation parameters of CD4
+ T
lymphocytes.
Keywords CD4
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Introduction
Chronic kidney disease (CKD) is characterized by slow loss
of kidney function over a period of years. The goal of CKD
treatment is to delay progression of the disease, but when the
patient reaches stage 5 of CKD (end-stage renal disease—
ESRD), renal replacement therapy (dialysis or kidney
transplantation) is necessary [1]. Apart from uremia, electro-
lyte disturbances, hypertension, and anemia, CKD patients
also present inappropriate parameters of nonspecific and
specific immunity. The most frequent findings include
abnormally high activity of monocytes based on production
of proinflammatory cytokines: tumor necrosis factor-alpha
(TNF-α), interleukin (IL)-1, and IL-6 [2, 3]. It is also
reported that CKD patients present decreased percentages of
peripheral T lymphocytes, both CD4
+ and CD8
+ cells, and B
lymphocytes in the blood [4, 5]. Furthermore, decreased IL-2
and interferon gamma production as an answer to stimulation
are observed in CKD patients [6, 7]. A detailed study
revealed that stimulated CD4
+ T lymphocytes of CKD
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DOI 10.1007/s10875-011-9603-xpatients present decreased expression of antigens involved in
T lymphocyte activation: major co-stimulatory CD28 antigen
and early activation antigen CD69 [7]. The decreased levels
of these antigens, especially CD28, could be one of the
reasons for deficient reactions of T lymphocytes. CD28
regulates IL-2 production on the transcriptional level [8], and
its lower expression explains reduced levels of IL-2 in
response to mitogenic stimulation in CKD patients. Also,
fewer CD4
+CD28
+ lymphocytes of CKD patients proliferate
in vitro, and these cells require more time to enter the first
phase (G1) of the cell cycle [7]. CD4
+ T lymphocytes are
involved in both cell-mediated and humoral immune
responses; consequently, their changed phenotype and dis-
turbances in proliferation kinetics lead to impaired immunity
observed as decreased immunoglobulin production by B
lymphocytes resulting in poor response of CKD patients to
vaccination and increased susceptibility to infections [9].
There is still little known about the mechanisms that
cause immunological deficiency in CKD, but it seems that
these changes are deepened mainly by hemodialysis (HD)
procedures. At least, all the aforementioned disturbances in
cellular and humoral immunity were described in HD
patients. Dialytic membrane incompatibility, bacterial
contamination of dialyzer, and vascular access are the
main reasons for inflammatory response in CKD
patients. Direct contact of peripheral blood mononuclear
cells (PBMC) with artificial membrane initiates abnor-
mal production of proinflammatory cytokines by mono-
cytes [10]. Furthermore, the HD procedure induces also
apoptosis of T lymphocytes, which leads to T cell
lymphopenia observed in patients [11]. However, it is
not clear if changes in phenotype, cytokine production,
and proliferation of T lymphocytes result only from
repeated hemodialysis procedure or are connected with
CKD progression, since there are no detailed studies
comparing these parameters in hemodialyzed and predial-
ysis CKD patients. Most of the articles focus only on
numbers or proportions of lymphocytes in the blood of
patients. Meanwhile, surface antigens of lymphocytes and
their proliferation kinetics are the key parameters crucial
for cell-mediated and humoral responses. Therefore, we
have chosen for our study the molecules crucial for the
activity of CD4
+ T lymphocytes (CD28 antigen—co-
stimulatory molecule important for antigen presentation;
activation markers—CD69 (early), CD25, CD95 (middle),
HLA-DR (late)) and analyzed their expression along with
proliferation parameters of T CD4
+ lymphocytes in
hemodialyzed and predialysis patients.
Patients and Methods
Patients The study groups consisted of 25 CKD patients
(mean age 60.32±17.92 years) and 14 healthy individuals
(mean age 53.14±11.55 years). The 15 patients underwent
5-h sessions of hemodialysis three times a week. The
average time of hemodialysis was 1.18±0.57 months with
the shortest time of 2 weeks and the longest of 2 months.
Ninety-five percent of examined CKD patients were CMV
seropositive but none of them presented symptoms of an
active infectious process during the study. Ten patients were
treated conservatively (predialysis patients). The study has
been approved by the Ethical Committee of the Medical
University of Gdańsk. The main features of patients and
controls are presented in Table I. Mean hemoglobin was
significantly decreased in all groups of patients with CKD
when compared to healthy control. All patients had stage 5
of CKD (ESRD) (Table I).
Stainings and Flow Cytometry Analysis of Antigens of
CD4
+ Lymphocytes Thirty milliliters of venous peripheral
blood was collected in tubes containing EDTA as the
anti-coagulant from each HD patient before the HD
session and from patients treated conservatively and
healthy volunteers. Five milliliters of blood was designed
for morphology. Samples of 50 μl per tube blood were
transferred for staining with monoclonal antibodies ex
vivo and red blood cell lysis. Blood cells were stained
with FITC-conjugated anti-CD3, RPE-Cy5-conjugated
anti-CD4 (DAKO, Denmark), PE-conjugated anti-CD28,
PE-conjugated anti-CD69 (BD-Pharmigen, USA), PE-
conjugated anti-CD25 (DAKO, Denmark), PE-
conjugated anti-CD95, and PE-conjugated anti-HLA-DR
(BD-Pharmigen) antibodies and incubated for 30 min at
4°C.
After antibody staining, red blood cells were lysed
with buffer containing 0.8% NH4Cl and 0.1% KHCO3.
Finally, cells were resuspended in 200 μlo fP B Sb u f f e r
Table I Basic characteristics of
patients and controls
*p<0.05 vs. control group, t test
for independent groups
Predialysis patients Hemodialyzed patients Control
Number 10 15 14
Age (years) 57.66±19.28 62.15±17.46 53.14±11.55
Sex (M/F) 7/3 11/4 9/5
GFR (min/ml/1.73 m
2) 13.10±5.53 10.68±3.27 >60
Hemoglobin (g/dl) 10.51±1.33* 9.86±1.03* 14.04±0.73
190 J Clin Immunol (2012) 32:189–200for final flow cytometric analysis. Twenty milliliters of
venous blood was designed for PBMC isolation by
centrifugation on Histopaque™ gradient (Sigma Chemical
Co., USA).
PBMC In Vitro Stimulation and Dividing Cell Tracking The
dividing cell tracking method used to examine differences
in proliferation rate and the percentage of dividing cells
were based on Hasbold’s method [12] and modified using
the method of Witkowski et al. [13]. The advantage of this
method allows to stimulate the peripheral blood mononu-
clear cells without their purification before and to analyze
the different subpopulations of dividing cells by staining
with different monoclonal antibodies and using flow
cytometry. The comparison between different subpopula-
tions from one person is very valuable because the
stimulation conditions are the same; therefore, the observed
differences in kinetics are dependent on cell type, not on
different stimulation conditions.
Twelve million of PBMC were stained with 3 μM CFSE
(Sigma Chemical Co.) for 15 min in the dark at 37°C and
washed one time with complete medium supplemented with
0.5% FBS and two times with complete medium. Then
cells were stimulated with immobilized anti-CD3 antibody
(250 ng per 2 million cells in 2 ml of complete medium)
and incubated for 5 days at 37°C, 5% CO2. The same
conditions were applied to the unstimulated PBMC as
negative control. Stimulated and unstimulated cells were
collected after 72 and 120 h and stained with RPE-Cy5-
conjugated anti-CD4 (DAKO), PE-conjugated anti-CD28,
PE-conjugated anti-CD69 (BD-Pharmigen), and PE-
conjugated anti-CD25 (DAKO) antibodies for 30 min at
Fig. 1 Flow cytometric analysis
of subpopulations and prolifera-
tion of T lymphocytes ex vivo
and in vitro. Whole blood cells
were stained with monoclonal
antibodies against CD3, CD4,
and CD28 antigens. First, T
lymphocytes were selected on
the basis of their forward and
side scatter characteristics (a)
and CD3 expression (b). Finally,
CD3
+ T lymphocytes were
visualized in dot-plot showing
CD4 and CD28 (or other
antigen) on the x- and y-axes,
respectively (c). Meanwhile,
proliferating T lymphocytes
(stained with CFSE as described
in “Patients and Methods”) were
also selected on the basis of
their forward and side scatter
characteristics (d). Next, the
subpopulation of lymphocytes
of interest (for example
CD4
+CD28
+ cells) was gated (e)
and their divisions were shown
in histogram (f)
J Clin Immunol (2012) 32:189–200 1914°C. After washing, cells were resuspended in 200 μlo f
PBS buffer for flow cytometric analysis performed directly
after sample preparation.
Analysis and Statistics Quantitative fluorescence analysis
was performed on FACScan (Becton Dickinson, USA).
Expression of surface antigens measured as mean fluores-
Fig. 3 ComparisonofCD4
+CD28
+ and CD4
+CD28
− of subpopulations
of T lymphocytes ex vivo. Graphs demonstrate the percentages of
CD4
+CD28
+ (a) and CD4
+CD28
− (b) cells in all examined groups.
Midpoints of figures present medians, boxes present 25–75%, and
whiskers outside present the minimum and maximum of all the data,
Kruskal–Wallis test
Fig. 2 Comparison of populations of main T lymphocytes ex vivo.
Graphs show percentages of main populations: CD3
+ (a), CD4
+ (b),
and CD8
+ (c) as well as CD4/CD8 ratio (d) in all examined groups—
healthy controls (Control), hemodialyzed patients (HD), and predialysis
patients (PD). Midpoints of figures present medians, boxes present 25–
75%, and whiskers outside present the minimum and maximum of all
the data, Kruskal–Wallis test
192 J Clin Immunol (2012) 32:189–200cence intensity (MFI) and the percentage of CD4
+ T
lymphocytes were analyzed with the Cyflogic, version
1.2.1 (© Perttu Terho and © CyFlo Ltd).
Gating strategy: Ex vivo, T lymphocytes were selected
on the basis of their forward and side scatter characteristics
and CD3 expression (Fig. 1). Isotype control (MultiMix™
Triple-Colour Control Reagent, DAKO) was used to
determine the positive subpopulation of CD4
+ T lympho-
cytes expressing CD28, CD69, CD25, CD95, or HLA-DR
antigen. The percentage of positive T cells was calculated
as the percentage of CD4
+ T lymphocytes.
Proliferating T lymphocytes were also selected on the
basis of their forward and side scatter characteristics
(Fig. 1d). Next, the population of lymphocytes of interest
was gated (Fig. 1e) and their divisions were shown in
histogram (Fig. 1f). Calculation of cell cycle kinetics
(G0→G1 time, cell cycle duration, number of divisions
per one cell, and number of finished divisions) of
CD4
+CD28
+ and CD4
+CD28
− cells was performed accord-
ing to the Witkowski protocol [13].
Statistical analysis was done using the computer program
Statistica, version 8 (StatSoft, Poland). The significance tests
were chosen according to the data distribution (as indicated in
the “Results”). Due to irregularly distributed variances,
appropriate nonparametric tests were applied. The level of
significance in all was p≤0.05.
Results
Composition of Subpopulations of Main T Lymphocytes Ex
Vivo No changes were seen in the percentage of T
lymphocytes (CD3
+ cells) between PD patients, HD patients,
and healthy controls ex vivo (Fig. 2a). Also, we did not
observe any differences in proportions of CD4
+ and CD8
+ T
lymphocytes as well as in CD4/CD8 ratio in all examined
groups (Fig. 2b–d). There was no difference in the
proportions of CD4
+CD28
+/CD4
+CD28
− lymphocytes in
all examined groups (Fig. 3). The percentages of main active
Fig. 4 Comparison of subpopulations of main active CD4
+ T
lymphocytes ex vivo. Graphs demonstrate the percentages of
CD4
+CD69
+ (a), CD4
+CD25
+ (b), CD4
+CD95
+ (c), and CD4
+HLA-
DR
+ (d) cells in all examined groups. Midpoints of figures present
medians, boxes present 25–75%, and whiskers outside present the
minimum and maximum of all the data, Kruskal–Wallis test
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+ T lymphocyte subpopulations, that is, CD4
+CD25
+,
CD4
+HLA-DR
+,C D 4
+CD69
+,o rC D 4
+CD95
+ cells, were
also at similar level in patients and healthy controls (Fig. 4).
In Vitro Studies of Subpopulations of Main CD4
+ T
Lymphocytes and Their Antigens The percentages of
CD4
+CD28
+ and CD4
+CD25
+ T lymphocytes of HD
patients were significantly decreased after 72 and 120 h of
stimulation with anti-CD3 antibody when compared to
predialysis patients and healthy controls (Fig. 5).
The major findings of the study were related to changes
in the expression of CD28, CD25, and CD69 antigens on
CD4
+ T lymphocytes measured as MFI. Stimulated CD4
+ T
lymphocytes of HD patients presented decreased expression
of co-stimulatory molecule CD28 when compared to
predialysis patients and healthy controls (Fig. 6a, b). The
expression of middle activation antigen CD25 (Fig. 6c, d)
and early activation antigen CD69 (Fig. 6e, f) was also
l o w e ri nH Dp a t i e n t sa sc o m p a r e dt ot h eo t h e rt w o
examinedgroups.ThegroupofHDpatientswascharacterized
both by a lower percentage of cells with co-stimulatory and
activation antigensand bya reduced level ofthese antigenson
a single cell. In contrast to HD patients, CD4
+ Tl y m p h o c y t e s
obtained from PD patients presented levels of CD28, CD25,
and CD69 similar to those observed in healthy controls.
In Vitro Studies of the Proliferation of CD4
+CD28
+ and
CD4
+CD28
− T Lymphocytes HD patients showed a signifi-
cantly decreased percentage of CD4
+CD28
+ lymphocytes
proliferating after stimulation with the anti-CD3 antibody
(Fig. 7a, b) when compared to PD patients and healthy
controls. The duration of cell cycle of CD4
+CD28
+ cells was
similar in all examined groups (Fig. 7c), while the calculated
period of time required by these cells to enter the G1 phase
(the G0→G1 time) was longer in HD patients compared to
healthy controls (Fig. 7d).
The general number of divisions of proliferating
CD4
+CD28
+ T lymphocytes did not vary between all
examined groups (Fig. 8a), but the number of divisions
per one cell and the number of finished divisions were
significantly reduced in HD patients when compared with
healthy controls after 72 h of stimulation (Fig. 8b, c).
Fig. 5 Proportions of CD4
+CD28
+ and CD4
+CD25
+ T lymphocytes in
vitro. Graphs present the percentages of CD4
+CD28
+ and CD4
+CD25
+
cells after 72 h (a, c) and 120 h (b, d) of stimulation with anti-CD3
antibody in examined groups. Midpoints of figures present medians,
boxes present 25–75%, and whiskers outside present the minimum and
maximum of all the data, *p<0.05, Kruskal–Wallis test
194 J Clin Immunol (2012) 32:189–200Moreover, a decreased number of divisions per one cell
was positively correlated with a decreased percentage of
proliferating CD4
+CD28
+ lymphocytes (Fig. 8d)a n d
negatively correlated with longer G0→G1 time (Fig. 8e)
in that group of patients. Also, a decreased number of
finished divisions was negatively correlated with longer
G0→G1 time (Fig. 8f).
No changes were seen in the percentage of proliferating
CD4
+CD28
− T lymphocytes between HD and PD patients
and healthy controls (Fig. 9a). Also, the general number of
Fig. 6 Changes in the expression of CD28, CD69, and CD25
antigens on CD4
+ T lymphocytes in vitro. Graphs show the
expression of CD28, CD69, and CD25 antigens on CD4
+ T
lymphocytes after 72 h (a, c, e) and 120 h (b, d, f) of stimulation
with anti-CD3 antibody in all examined groups. Midpoints of figures
present medians, boxes present 25–75%, and whiskers outside present
the minimum and maximum of all the data, *p<0.05, Kruskal–Wallis
test. MFI mean fluorescence intensity
J Clin Immunol (2012) 32:189–200 195divisions or number of divisions per one cell did not vary
between all examined groups (Fig. 9b, c).
Discussion
Immunological response mediated by T lymphocytes is
known to be weakened in CKD patients. The influence of
hemodialysis on immune response is intensively discussed
and brings many contradictory information. The majority of
the studies show that the numbers of CD3
+, CD4
+, and
CD8
+ cells are decreased in HD patients and postulate that
the HD procedure induces apoptosis of T lymphocytes [11,
14]. Our previous studies showed that HD patients
demonstrate disturbances in subpopulations of activated
CD4
+ T lymphocytes ex vivo, presented by significantly
higher percentages of CD4
+CD95
+ and CD4
+HLA-DR
+
and a lower percentage of CD4
+CD69
+ cells [7]. Also,
CD4
+ T lymphocytes of HD patients after stimulation with
anti-CD3 antibody exhibit decreased expression of antigens
crucial for their activation and proliferation [7]. The
disturbances in phenotype and proliferation of CD4
+ T
lymphocytes can be fundamental for deficient cellular and
humoral responses in CKD. The question is if these
changes depend only on continuous hemodialysis or are
strictly connected with CKD progression leading to kidney
failure. Therefore, we examined the main parameters of the
immune responses of CD4
+ T lymphocytes and compared
them in hemodialyzed and predialysis patients and healthy
controls.
Studies ex vivo showed that the percentage of CD3
+
lymphocytes and the percentages of their main populations
CD4
+ and CD8
+ cells are comparable in all examined
groups. These observations are very interesting in the
context of the data of Borges and colleagues presenting a
significant decrease in these particular populations of
lymphocytes [11]. However, these parameters were mea-
sured immediately after the HD procedure, while our blood
samples were collected from each patient before the HD
session. This observation indicates that a single contact of
PBMC with the dialytic membrane can induce apoptosis of
Fig. 7 Changes in main cell cycle parameters of CD4
+CD28
+ T
lymphocytes. Graphs present the percentage of proliferating
CD4
+CD28
+ cells after 72 h (a) and 120 h (b) of stimulation with
anti-CD3 antibody, cell cycle duration (c), and time between phase G0
and G1 (d)i ne x a m i n e dg r o u p s .Midpoints of figures present medians,
boxes present 25–75%, and whiskers outside present the minimum and
maximum of all the data, *p<0.05, Kruskal–Wallis test
196 J Clin Immunol (2012) 32:189–200T lymphocytes. There are studies showing increased
apoptosis of T lymphocytes of CKD patients, mainly Th1
subpopulation, in comparison to healthy controls [15].
According to Alvarez-Lara et al., Th1 lymphocytes of
patients presented decreased expression of anti-apoptotic
molecule Bcl-2, which made them more susceptible to
undergo apoptosis, independent of exposure to the dialytic
membrane [15]. The mechanisms underlying these results
are not known and it is suggested that uremic toxins can act
directly on lymphocytes. If this is the case, it is not clear
why only Th1 lymphocytes would be more sensitive to
these toxins. Anyway, it seems that different results come
Fig. 8 Comparison of the number of divisions of CD4
+CD28
+ T
lymphocytes and their correlations with other cell cycle parameters.
Graphs present the general number of divisions (a), the number of
divisions per one cell (b), and the number of finished divisions (c)
after 72 h of stimulation with anti-CD3 antibody in examined groups.
Midpoints of a–c present medians, boxes present 25–75%, and
whiskers outside present the minimum and maximum of all the data,
*p<0.05, Kruskal–Wallis test. d–f Spearman R correlation
J Clin Immunol (2012) 32:189–200 197mainly from various methods of preparing blood samples
and experimental models used by the authors.
Since there are articles describing the impact of CMV
seropositivity on CD4
+ T lymphocyte subsets, especially
the increase of the number of circulating CD4
+CD28
− cells
in ESRD patients [16, 17], we also examined the
proportions of CD4
+CD28
+/CD4
+CD28
− lymphocytes ex
vivo. The percentage of circulating CD4
+CD28
+ lympho-
cytes in both groups of patients was not decreased in favor
of expansion of CD4
+CD28
− cells as compared to healthy
people. No activation-related phenotype of T lymphocytes
ex vivo (both early and late) in all examined groups was
seen that could indicate that both HD and PD patients did
not present an enhanced inflammatory response during the
study.
The in vitro experiments showed both significantly
lower proportions of CD4
+CD28
+ and CD4
+CD25
+ cells
and reduced expression of CD28, CD25, and CD69
antigens only in HD patients, in contrast to PD patients,
who had comparable values as the healthy controls. Lower
levels of these antigens on CD4
+ T lymphocytes of HD
patients strongly indicate that the repeated hemodialysis
procedure is the major factor influencing the phenotype of
CD4
+ T lymphocytes. These changes appear independently
of the patients’ immunological status ex vivo, as both HD
and PD patients presented the proportions of subpopula-
tions of main CD4
+ T lymphocytes similar to those
observed in healthy controls.
Changes in phenotype of CD4
+ T lymphocytes of HD
patients consequently lead to changes in their proliferation
parameters. HD patients showed lower percentage of
proliferating CD4
+CD28
+ lymphocytes when compared to
PD patients and healthy controls. There was no difference
between cell cycle duration between all examined groups,
but CD4
+CD28
+ lymphocytes of HD patients were charac-
terized by longer time between G0 and G1 phases of cell
cycle. We already demonstrated that there is a strict
connection between the level of co-stimulatory molecule
CD28 on CD4
+ T lymphocytes and the time needed for
response to stimulation [18]. This observation was described
for healthy people [18]a sw e l la si nH Dp a t i e n t sn o t
receiving rhEPO [7]. Analysis of the cell cycle also revealed
that proliferating CD4
+CD28
+ T lymphocytes of HD patients
apart from prolonged G0→G1 time are also characterized by
reduced numbers of finished divisions and divisions per one
cell in 72 h of stimulation. Meanwhile, CD4
+ Tl y m p h o c y t e s
of predialysis patients present cell cycle parameters compa-
rable with those of healthy controls.
Changes in cell cycle kinetics did not concern the
population of CD4
+CD28
− T lymphocytes in all examined
groups, meaning that the main subpopulations changed by
Fig. 9 Comparison of main cell cycle parameters of CD4
+CD28
− T
lymphocytes. Graphs present the percentage of proliferating
CD4
+CD28
− cells (a), the general number of divisions (b), and the
number of divisions per one cell (c) after 72 h of stimulation with anti-
CD3 antibody in examined groups. Midpoints of a–c present medians,
boxes present 25–75%, and whiskers outside present the minimum and
maximum of all the data, Kruskal–Wallis test
198 J Clin Immunol (2012) 32:189–200hemodialysis are CD4
+CD28
+ T cells, which play a central
role in acquired immune response.
These observations indicate that repeated hemodialysis
procedure causes negative changes in the phenotype of
CD4
+ T lymphocytes of CKD patients. We have demon-
strated similar results in a previous article paying attention
to the immunomodulatory effects of rhEPO treatment in
these patients [7]. Our observations showed that rhEPO
administration to HD patients positively influences the
levels of crucial surface antigens and proliferation kinetics
of these cells [7]. Older studies have also shown that rhEPO
treatment causes a decline of TNF-α [19]. High levels of
TNF-α could be one of the reasons for lower CD28
expression in HD patients and at the same time indirectly
affect the proliferation of CD4
+CD28
+ T lymphocytes,
since TNF was shown to directly regulate transcription of
the CD28 gene [20] and also influence the CD28
expression on CD4
+ T cells in RA patients treated with
anti-TNF [21]. IL-6 is the second proinflammatory cytokine
that inhibits differentiation of Th1 lymphocytes [22].
Therefore, one of the depressing effects of repetitive
hemodialysis on T lymphocytes could be dependent on
the high levels of these proinflammatory cytokines. On the
other hand, blood was collected prior to HD session, before
monocytes had any contact with the dialytic membrane.
Since there is a predominance of Th1 over Th2 lympho-
cytes in HD patients [23] in opposition to predialysis
patients, who mainly exhibit a Th2 response [24], changes
in phenotype of CD4
+ T lymphocytes of HD patients could
result from cytokine imbalance.
On the other hand, stress-induced premature senescence
(SIPS), a process that involves changes in the function and
morphology of cells and is detected among others by
telomere shortening, could be another explanation of
deficient reactions of CD4
+ T lymphocytes of HD patients.
Some time ago, Jimenez and colleagues presented the
theory of SIPS in CKD [25]. They found the subpopulation
of lymphocytes with short telomeres in CKD patients and
noticed that the mean telomere length was significantly
decreased in mononuclear cells from HD patients treated
with cellulosic membranes when compared with non-
cellulosic and predialysis patients [25]. Lymphocytes of
CKD undergo SIPS and repeated hemodialysis procedure
deepens this process. In our study, CD4
+ T lymphocytes of
HD patients present lower CD28 and CD25 expression,
another sign of proliferative senescence [16, 26, 27].
Conclusions
For the moment, the mechanisms underlying deficient
reactions of CD4
+ T lymphocytes of HD patients remain
an open question, and additional studies are needed to
explain these observations. However, disturbances in the
activation parameters of T lymphocytes could result from
the presence of uremic toxins and proinflammatory cyto-
kines, or be related to their early proliferative senescence,
which is deepened by continuous hemodialysis.
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